Background Familial hypercholesterolemia (FH) is a monogenic disorder characterized by
elevated low-density lipoprotein cholesterol (LDL-C). A FH causing genetic variant in LDLR …

Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein
cholesterol (LDL-C) levels and a high risk of early coronary heart disease. Structural …

BACKGROUND: Recent findings suggest that DNA methylation, a well-known epigenetic
mechanism, is involved in high-density lipoprotein cholesterol (HDL-C) metabolism and …

Aim: This study aims to assess whether epigenetic changes may account for high-density
lipoprotein cholesterol (HDL-C) level variability in familial hypercholesterolemia (FH), a …

Aim: Methylation of LDLR, PCSK9 and LDLRAP1 CpG sites was assessed in patients with
familial hypercholesterolemia (FH). Methods: DNA methylation of was analyzed by …

Gene polymorphisms associated so far with plasma lipid concentrations explain only a
fraction of their heritability, which can reach up to 60%. Recent studies suggest that …

Background Familial hypercholesterolaemia (FH) is an autosomal dominant disease of lipid
metabolism, which leads to early coronary heart disease. Mutations in LDLR, APOB and …

Aim: Familial hypercholesterolemia (FH) is the most commonly encountered genetic
condition that predisposes individuals to severe autosomal dominant lipid metabolism …

Familial hypercholesterolemia (FH) is a monogenic disease characterized by high plasma
low-density lipoprotein cholesterol (LDL-c) levels and increased risk of premature …

During the last 2 years, the cardiovascular disease (CVD) field has increasingly embraced
epigenomics technologies. This ménage is a young one in comparison with cancer studies …